Stock picks with research | support | resistance and technical analysis for trading | Day trading | stock investing in the market
day investing picks penny stock trading
Skip Navigation Links
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event

Join Now

Stock Research for Breakout trading

Advertise 2 ۩  Daily market forecast

NEKTAR THERAPEUTICS COM support | resistance | research

Stock : NKTR |   Stock Recommendations : Buy
Sector : Medical Equipment & Supplies |   First resistance : 7.26
Stock Name : NEKTAR THERAPEUTICS COM |   Second resistance : 13.15
Buy Near : 5.53 |   Third resistance : 17.00
StopLoss : 3.64 |   First Support : 3.64
Posted date : 11/2/2008 12:00:00 AM |   Second Support : 2.91

Nektar Therapeutics com (NKTR) given a nice double top breakout on 10/31/08 with good volume. Again many technical indicators also have given a buy signal, with

   rising moving average weekly and daily Stockhastic given a buy signal and ADX also given a buy signal. Nektar Therapeutics com (NKTR) reported positive Phase 1 data for its lead proprietary oncology product candidate, NKTR-102. As per technical indicator analysis this Stock looks good candidate for portfolio investment and also for day trading, Stock investing, trend trading | swing trading. Due to Stock market and economic condition keep tight stop loss on all position. Buy with our first target $7.26 and keep stop loss $3.64

Stock research

Recent News Head Lines
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
(Fri, 29 May 2020 21:00:00 +0000)
Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. EDT during EULAR 2020. The event will follow Thursday's virtual poster presentation of the data from a Phase 1b multiple ascending dose study of NKTR-358, a first-in-class investigational regulatory T cell stimulator, in patients with systemic lupus erythematosus.
7 Stocks Maverick Capital Continues to Buy
(Tue, 26 May 2020 15:11:35 +0000)
Adobe and Avantor make the list Continue reading...
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
(Fri, 22 May 2020 12:30:00 +0000)
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery on BEMPEG, a CD122-preferential IL-2 pathway agonist, demonstrated that when administered as a monotherapy, it was well tolerated and showed clinical activity, including tumor shrinkage and durable disease stabilization, in heavily pretreated patients with solid tumor cancers.1 The manuscript published today presents the safety, immune-activation and efficacy results from a Phase 1 dose-escalation study conducted in 38 patients with immunotherapy-naïve, advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).
Is There An Opportunity With Nektar Therapeutics's (NASDAQ:NKTR) 46% Undervaluation?
(Mon, 18 May 2020 12:05:07 +0000)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Nektar Therapeutics...
Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics
(Sun, 17 May 2020 23:13:01 +0000)
Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22.02.

Never go against major trend for day trading | breakout stock trading Before to invest learn day trading strategies online stock trading system stock investing tips stock research .

Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006
Chart courtesy of
Breakout Stock trading - Nektar Therapeutics com research | day trading | stock investing

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.